文献速递骨质疏松与代谢性骨病

COVID-19对骨质疏松症治疗的影响:IOF-NOF-ESCEO全球调查

How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey.
PubMed 文献 · Osteoporos Int · 2021-02-08

国际骨质疏松基金会、美国国家骨质疏松基金会和欧洲骨质疏松和骨关节炎临床经济学会联合开展全球问卷调查,评估COVID-19对骨质疏松症管理的影响。结果显示远程医疗咨询增加、DXA扫描延迟、药物供应中断和肠外药物给药减少。

要点

  • 远程医疗咨询增加:33%电话咨询,21%视频咨询。
  • 仅29%的受访者能按推荐进行DXA扫描。
  • 43%的临床医生难以安排适当的骨质疏松药物。

核心结论

  • COVID-19大流行导致骨质疏松症管理中远程医疗咨询增加、DXA扫描延迟、药物供应中断和肠外药物给药减少。

研究设计与样本

  • 通过电子方式向IOF和NOF成员发放问卷,收集定量数据进行分析,并对定性数据进行主题归纳。

主要发现

  • 共收到来自53个国家的209名医疗卫生工作者的回复,其中欧洲28%、北美24%、亚太19%、中东17%、拉丁美洲12%。
  • 受访者中医生占85%,主要专业为风湿病学(40%)、内分泌学(22%)和骨科(15%)。
  • 33%的受访者进行电话咨询,21%进行视频咨询。
  • 仅29%的受访者能按推荐获得DXA扫描。
  • 60%的临床医生有系统识别接受肠外给药的患者,43%的临床医生报告在COVID-19危机期间难以安排适当的骨质疏松药物。

临床怎么用

  • 临床医生应关注COVID-19期间骨质疏松症管理中远程医疗的合理应用。
  • 需注意DXA扫描延迟和药物供应中断对患者管理的影响,并制定应对策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The effects of COVID-19 have the potential to impact on the management of chronic diseases including osteoporosis. A global survey has demonstrated that these impacts include an increase in telemedicine consultations, delays in DXA scanning, interruptions in the supply of medications and reductions in parenteral medication delivery. INTRODUCTION: The COVID-19 pandemic has had profound effects on the health of the global population both directly, via the sequelae of the infection, and indirectly, including the relative neglect of chronic disease management. Together the International Osteoporosis Foundation and National Osteoporosis Foundation sought to ascertain the impact on osteoporosis management. METHODS: Questionnaires were electronically circulated to a sample of members of both learned bodies and included information regarding the location and specialty of respondents, current extent of face to face consultations, alterations in osteoporosis risk assessment, telemedicine experience, alterations to medication ascertainment and delivery and electronic health record (EHR) utilisation. Responses were collected, quantitative data analysed, and qualitative data assessed for recurring themes. RESULTS: Responses were received from 209 healthcare workers from 53 countries, including 28% from Europe, 24% from North America, 19% from the Asia Pacific region, 17% from the Middle East and 12% from Latin America. Most respondents were physicians (85%) with physician assistants, physical therapists and nurses/nurse practitioners represented in the sample. The main three specialties represented included rheumatology (40%), endocrinology (22%) and orthopaedics (15%). In terms of the type of patient contact, 33% of respondents conducted telephone consultations and 21% video consultations. Bone mineral density assessment by dual-energy X-ray absorptiometry (DXA) usage was affected with only 29% able to obtain a scan as recommended. The majority of clinicians (60%) had systems in place to identify patients receiving parenteral medication, and 43% of clinicians reported difficulty in arranging appropriate osteoporosis medications during the COVID-19 crisis. CONCLUSIONS: To conclude through surveying a global sample of osteoporosis healthcare professionals, we have observed an increase in telemedicine consultations, delays in DXA scanning, interrupted supply of medications and reductions in parenteral medication delivery.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Fuggle NR, Singer A, Gill C, et al. How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporos Int. 2021. PMID: 33558957. doi:10.1007/s00198-020-05793-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。